Co-Authors
This is a "connection" page, showing publications co-authored by Loredana Sarmati and Marco Iannetta.
Connection Strength
3.032
-
T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers. Mult Scler Relat Disord. 2021 Oct; 55:103157.
Score: 0.957
-
Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study. Sci Rep. 2021 06 17; 11(1):12762.
Score: 0.951
-
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. Mult Scler Relat Disord. 2020 Oct; 45:102442.
Score: 0.896
-
Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients. EBioMedicine. 2021 Apr; 66:103341.
Score: 0.059
-
Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. Life (Basel). 2020 Nov 23; 10(11).
Score: 0.057
-
Depressive and anxiety symptoms in patients with SARS-CoV2 infection. J Affect Disord. 2021 01 01; 278:339-340.
Score: 0.056
-
Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun. 2020 08; 88:11-16.
Score: 0.055